Flex partners with Google, launches BrightInsight
Ahead of the Healthcare Information & Management Systems Society (HIMSS), manufacturer Flex has announced its partnership with Google Cloud, and subsequent launch of BrightInsight.
A healthtech solution developed to provide drug and device data, BrightInsight will produce real-time insights. Built on a Google Cloud Platform, it enables customers to continually improve patient outcomes.
Set to be showcased at HIMSS, the technology has been developed with a robust Quality Management System that is designed for ISO 13485 and HIPAA compliance. Flex is also applying for HITRUST certification.
The McKinsey Global Institute estimates that applying big-data strategies to better inform healthcare-related decision making could generate up to $100bn in value annually across the US healthcare system.
Medical devices collect massive amounts of data, creating enormous potential for a rapid feedback loop that can help improve patient care and enhance drug therapy delivery and management. However, in order to make an impact, the data needs to be aggregated from a myriad of apps and stand-alone devices, as well as analysed to provide actionable insights.
BrightInsight works to solve such challenges and helps patients and health care professionals to better understand medical device usage and medication adherence and streamline the product development and certification process.
"We saw the need for a secure cloud platform designed to support highly-regulated connected drug delivery and medical devices, going beyond simple connectivity to deliver real-time intelligence and actionable insights," explained Kal Patel, MD, Senior Vice President of Digital Health for Flex.
- Former Uber CEO Travis Kalanick joins health startup Kareo
- Merck acquires Aussie immunotherapies company Viralytics for US$394mn
- Microsoft releases new health solutions utilising cloud tech
"With our 20 years of experience operating in global regulated medical environments and having deployed more than 75 regulated hardware and software medical products, Flex can combine our cross-industry capabilities to simplify our customers' digital transformation."
By collaborating with Google Cloud, Flex will gain the ability to deliver insights through customisable analytics dashboards fuelled by the company’s advanced machine learning and artificial intelligence (AI) capabilities.
Selected as a result of its exceptional track record for data security, Google’s Cloud Platform will enable BrightInsight to successfully securely store, analyse and gain insights from health information, without pharmaceutical and medical technology customers having to manage the underlying infrastructure. Advanced use may include controlling connected devices, drug dosing, decision support, personalised patient interventions, trend analysis and AI-driven insights.
"With a partner like Flex, we will enable our customers to develop innovative solutions and leverage machine learning-based analytics that can turn new data sets from wearables, medical devices, therapies and apps into actionable information for patients and providers," explained Gregory Moore, MD, PhD, Vice President, Healthcare, Google Cloud.
BrightInsight is designed to support CE-marked and FDA-regulated Class I, II and III medical devices, combination products and Software as a Medical Device requirements, enabling automated interventions. Deployed as a managed service, the BrightInsight platform allows pharmaceutical and medical technology companies to accelerate their time to market, reduce the cost of implementation and maintenance across multiple products, and scale for global markets.
Featuring foundational capabilities for rapid development and a modular platform architecture to support customisation and worldwide implementation, BrightInsight is built to securely manage highly regulated medical device data and personal health information.
Flex has put processes in place to monitor security and threat prevention to meet global compliance standards, where BrightInsight eliminates regulatory bottlenecks that can lead to costly delays by offering turnkey regulatory design control and file management of master files with the FDA. This service enables pharmaceutical and medical technology companies to focus on their drug, device or combination product submissions without the burden of documenting the software platform.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”